Group 1 - The total margin balance of A-shares reached 27,254.40 billion yuan on January 26, increasing by 19.65 billion yuan from the previous trading day, accounting for 2.62% of the A-share circulating market value [1] - The trading volume of margin transactions on the same day was 3,114.07 billion yuan, an increase of 79.37 billion yuan from the previous trading day, representing 9.48% of the total A-share trading volume [1] Group 2 - Among the 31 primary industries, 17 industries experienced net financing inflows, with the non-ferrous metals industry leading with a net inflow of 3.235 billion yuan [3] - Other industries with significant net financing inflows included electric power equipment, pharmaceutical biology, basic chemicals, and non-bank financials [3] Group 3 - A total of 53 stocks had net financing inflows exceeding 100 million yuan, with China Ping An leading at a net inflow of 444 million yuan [3] - Other notable stocks with high net financing inflows included Northern Rare Earth, China Aluminum, Western Mining, Maiwei Co., Oriental Fortune, Luoyang Molybdenum, Heng Rui Medicine, TBEA, and Industrial Bank [3][4]

Core Viewpoint - The Shanghai 180 ETF Index Fund (530280) has shown a positive performance with a recent increase of 0.96%, reflecting a stable market trend and investor interest in the underlying assets [1]. Performance Summary - As of January 26, 2026, the Shanghai 180 Index (000010) increased by 0.22%, with notable gains from stocks such as Zijin Mining (up 10.00%) and China National Offshore Oil Corporation (up 6.66%) [1]. - The Shanghai 180 ETF Index Fund has experienced a cumulative increase of 0.24% over the past week [1]. - The fund's year-to-date maximum drawdown is 1.30%, with a relative benchmark drawdown of 0.06% [3]. Liquidity and Trading Activity - The trading volume for the Shanghai 180 ETF Index Fund was 6.07 thousand yuan, with a turnover rate of 0.1% [1]. - The average daily trading volume over the past year was 177.38 thousand yuan [1]. Risk and Return Metrics - The fund has a Sharpe ratio of 2.12 since its inception, indicating a favorable risk-adjusted return [2]. - The tracking error over the past three months is 0.022%, demonstrating the fund's close alignment with the Shanghai 180 Index [5]. Fee Structure - The management fee for the Shanghai 180 ETF Index Fund is 0.15%, while the custody fee is 0.05% [4]. Top Holdings - As of December 31, 2025, the top ten weighted stocks in the Shanghai 180 Index account for 25.29% of the index, with notable companies including Kweichow Moutai and Ping An Insurance [5]. - The top ten stocks and their respective weightings are as follows: - Kweichow Moutai: 4.22% - Zijin Mining: 4.03% - Ping An Insurance: 2.87% - Hengrui Medicine: 2.46% - WuXi AppTec: 2.08% - China Merchants Bank: 2.04% - Cambricon Technologies: 1.97% - Yangtze Power: 1.88% - SMIC: 1.80% - Industrial Fulian: 1.79% [5].

北京商报讯(记者王寅浩宋雨盈)1月26日，恒瑞医药（600276）发布公告称，公司收到国家药品监督管 理局核准签发关于SHR-1049注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据公 告，SHR-1049注射液是创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上 市。 ...

| 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | 交易日期 | 证券简称 | 证券代码 | 卖出营业部 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 华泰证券股份有限 公司总部 | 圍) 看限公司 上海 | 2026-01-26 | 恒瑞医药 | 600276 | 5816 | 100 | 58.16 | 1月26日，恒瑞医药大宗交易成交100万股，成交额5816万元，占当日总成交额的1.35%，成交价58.16元，较市场收盘价58.16元持平。 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，恒瑞医药1月26日晚间发布公告称，近日，江苏恒瑞医药股份有限公司收到国家药品监督 管理局核准签发关于SHR-1049注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 王晓波） ...

Core Viewpoint - Heng Rui Medicine (600276)(01276) has received approval from the National Medical Products Administration for the clinical trial of SHR-1049 injection, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1: Drug Development - SHR-1049 injection is a self-developed innovative anti-tumor drug by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-1049 injection project is approximately 26 million yuan (unaudited) [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-012 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 剂 型：注射剂 申请事项：临床试验 受 理 号：CXSL2500956 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 7 日受理的 SHR-1049 注射液符合药品注册的有关要求，同意本品开展单 药在晚期实体瘤中的临床试验。 二、药物的其他情况 SHR-1049 注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实 体瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-1049 注射 液相关项目累计研发投入约为 2,600 万元(未经审计)。 三、风险提示 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发关于 SHR-1049 注射液的《药物临 床试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 一、药物的基本情况 ...

格隆汇1月26日丨恒瑞医药(01276.HK)发布公告，近日，公司收到国家药监局核准签发关于SHR-1049注 射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-1049注射液是公司自主研发的创 新型抗肿瘤药物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同类药物获批上市。 ...

每经AI快讯，1月26日，恒瑞医药（600276）(600276.SH)公告称，公司收到国家药监局核准签发关于 SHR-1049注射液的《药物临床试验批准通知书》，同意开展单药在晚期实体瘤中的临床试验。SHR- 1049注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同 类药物获批上市。 ...

格隆汇1月26日｜恒瑞医药公告，公司收到国家药品监督管理局核准签发关于SHR-1049注射液的《药物 临床试验批准通知书》，将于近期开展临床试验。SHR-1049注射液是公司自主研发的创新型抗肿瘤药 物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-1049注射 液相关项目累计研发投入约为2,600万元(未经审计)。 ...